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Abstract Bacterial toxins affecting Rho activity in microvas-
cular endothelial cells were employed to elucidate whether
endothelial Rho participates in regulating the migration of
monocytes across monolayers of cultured endothelial cells.
Inactivation of Rho by the Clostridium C3 exoenzyme resulted
in an increased adhesion of peripheral blood monocytes to the
endothelium and a decreased rate of transendothelial monocyte
migration. Cytotoxic necrotizing factor 1-mediated activation of
endothelial Rho also reduced the rate of monocyte transmigra-
tion, but did not affect monocyte^endothelium adhesion. Thus,
efficient leukocyte extravasation requires Rho signaling not only
within the migrating leukocytes but also within the endothelial
lining of the vessel wall. ß 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The directed migration of leukocytes across the vascular
endothelium into in£amed tissue is mediated through a cas-
cade of leukocyte^endothelium interactions. These range from
an initial contact resulting in leukocyte capturing to ¢rm ad-
hesion of the leukocytes on the apical side of the endothelium
and ¢nally to the transendothelial migration of the leukocytes
which is thought to require at least in some cases a regulated
opening and closure of the interendothelial cell^cell contacts
(for review see [1]). It is well established that the cytoskeleton
of the leukocytes is subject to marked rearrangements during
this migration process. Particularly pronounced are changes in
the actin cytoskeleton that occur during leukocyte adhesion,
polarization and migration in chemotactic gradients. Key reg-
ulators of these actin rearrangements are Rho GTPase family
members (for review see [2^4]). Among other things it has
been shown that Cdc42 and Rac1 participate in the regulation
of leukocyte cell polarity, lamellipodia formation and directed
migration and that monocyte transmigration through an en-
dothelial monolayer requires Cdc42 activity [5^7]. Moreover,
RhoA is speci¢cally required for monocyte tail retraction dur-
ing transendothelial migration and a RhoA/Rho kinase
(ROCK)-dependent signaling pathway is involved in trigger-
ing the rear end detachment of migrating neutrophils [8,9].
Mouse knockout models also support the role of Rho family
members in leukocyte migration since, e.g. targeted disruption
of the hematopoietic cell-speci¢c Rac2 causes general defects
in F-actin rearrangements and chemotaxis in mouse neutro-
phils [10].
In contrast to the clearly documented role of Rho family
members in leukocyte locomotion less is known about the
Rho-dependent regulation of the endothelial cytoskeleton dur-
ing leukocyte passage. While the endothelial actin-cytoskele-
ton and actomyosin dynamics regulated by myosin light chain
kinase have been shown to participate in regulating neutrophil
and monocyte transendothelial migration [11^15] Rho family
members have been linked mainly to the regulation of endo-
thelial cell^cell contacts. By using bacterial toxins inactivating
Rho proteins as well as by employing dominant-negative Rho
mutants and Rho kinase inhibitors Rho and Rac were shown
to regulate endothelial cell permeability and barrier function
[16^19]. At least in part this regulation could re£ect a role of
Rho family members in regulating cadherin-mediated cell^cell
adhesion which has been documented more precisely in epi-
thelial cells (for review see [20]). A role of Rho GTPases in
regulating transendothelial lymphocyte tra⁄c has been de-
duced from experiments analyzing the migration of lympho-
cytes through brain endothelial cell layers of high electrical
resistance which revealed an inhibitory e¡ect of Rho inacti-
vating toxins [21].
To establish whether endothelial Rho family members also
participate in regulating leukocyte migration through micro-
vascular endothelium, i.e. the site of the vasculature where
most leukocyte extravasation is occurring, we made use of a
cell culture model reproducing this transmigration event and
employed bacterial toxins to interfere with Rho activity. We
show that inactivation of endothelial Rho by Clostridium
limosum exoenzyme C3-triggered ADP ribosylation results in
a reduced rate of monocyte transmigration through mono-
layers of microvascular endothelial cells. A similar e¡ect is
observed when endothelial stress ¢bers are stabilized by acti-
vating Rho through deamidation of Gln-63 by Escherichia coli
cytotoxic necrotizing factor CNF1. Altering the state of active
Rho has no (CNF1) or a stimulatory e¡ect (C3) on monocyte
adhesion indicating that intraendothelial events required for
both monocyte adhesion and subsequent transendothelial mi-
gration are regulated through Rho-dependent signaling.
2. Materials and methods
2.1. Cells
Monocytes were isolated from human bu¡y coats by Ficoll-Paque
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and subsequent Percoll density gradient centrifugation [22]. Cells were
then kept overnight in McCoy’s 5a medium containing 15% fetal calf
serum (FCS) at 37‡C in 5% CO2 using hydrophobic Te£on bags and
used for transmigration or adhesion assays the next day.
Human dermal microvascular endothelial cells (HMEC-1), kindly
provided by Dr. F. Candal (Centers for Disease Control, Atlanta,
GA, USA), were cultured at 37‡C in 3% CO2 in MCDB131 supple-
mented with 10% FCSgold (PAA Laboratories, Co«lbe, Germany))
and 20 mM L-glutamine, 50 Wg/ml (at least 30 units/ml) gentamicin,
10 ng/ml epidermal growth factor, and 1 Wg/ml hydrocortisone.
2.2. Bacterial toxins
The E. coli cytotoxic necrotizing factor (CNF1) was puri¢ed as
described [23], lyophilized and dissolved in sterile H2O to prepare a
1 mg/ml stock solution. Prior to the actual experiment this stock so-
lution was diluted in HMEC-1 culture medium to yield a ¢nal con-
centration of 500 ng/ml. The C. limosum C3 exoenzyme could not be
used directly as it is not taken up by intact endothelial monolayers.
Therefore we made use of a fusion toxin (C2IN-C3) comprising the
entire C3 exoenzyme fused to the N-terminal part of the C2I compo-
nent of the Clostridium botulinum C2 toxin. In conjunction with the
membrane binding C2II protein the latter mediates cellular uptake of
the C2IN-C3 fusion toxin [24]. The C2IIa and the C2IN-C3 fusion
toxin (stock solutions at 100 Wg/ml each) were added to endothelial
monolayers at a concentration of 200 ng/ml, and the monolayers were
then incubated with the toxins for di¡erent times (between 2 and 16 h).
Subsequently, cells were washed and then kept in toxin-free medium
for the di¡erent assays. In one series of experiments the C2IN-C3
fusion toxin was present throughout the entire transmigration assay
to elucidate the e¡ect of the toxin on the monocytic Rho in our
experimental setup.
2.3. Transmigration assay
Transmigration assays were performed essentially as described pre-
viously [25]. Brie£y, 2.2U105 HMEC-1 were seeded on ¢bronectin-
coated 6.5 mm Transwell ¢lters with a 5 Wm pore size and grown to
con£uency. After 48 h, medium and non-adherent cells were removed,
and 600 Wl assay medium (MCDB131 supplemented with 10%
FCSgold and 20 mM L-glutamine, 50 Wg/ml (at least 30 units/ml)
gentamicin) were added to the lower compartment of a two-chamber
system separated by the Transwell ¢lters. 2U106 monocytes in 100 Wl
assay medium were added to the upper chamber, and cells were sub-
sequently incubated at 37‡C and 3% CO2 for 2 or 4 h. To analyze the
e¡ect of Rho activation or inactivation, endothelial cells were prein-
cubated for the times indicated in medium containing the bacterial
toxins. Before the addition of monocytes the toxin-containing medium
was replaced by fresh assay medium. Cells which had transmigrated
through the endothelial monolayer were recovered in the lower tissue
culture chamber and quanti¢ed by counting in a Coulter Counter Z2
(Coulter, Krefeld, Germany). Data are presented as percentages of
cells transmigrated across a toxin-treated as compared to a non-
treated monolayer. To verify the integrity of the endothelial mono-
layer after the assay, the upper chamber was washed twice with PBS,
¢xed, stained with Di¡ Quick (Dade Behring, Du«dingen, Switzerland),
air dried and mounted on glass slides for microscopical analysis. Ex-
periments were routinely carried out in quadruplicate.
2.4. Analysis of monocyte^endothelium adhesion, endothelial
permeability and transendothelial resistance
Monocyte adhesion to the toxin-treated vs. non-treated endothe-
lium was analyzed by quantifying myeloperoxidase activity of adher-
ent monocyte as described previously [14]. Moreover the toxin e¡ect
on endothelial barrier properties was elucidated by measuring both,
the transendothelial permeability towards macromolecules (HRP) and
the transendothelial electrical resistance as described [25].
2.5. Statistics
All data were evaluated by a Student’s t-test and P values 9 0.01
were considered signi¢cant. All error bars represent standard errors.
2.6. Immuno£uorescence
The e¡ect of the Rho-manipulating toxins on the actin cytoskeleton
and endothelial junction proteins was analyzed in HMEC-1 grown to
con£uency on ¢bronectin-coated coverslips. Following toxin treat-
ment cells were rinsed in PBS and then ¢xed in 3.7% formaldehyde
in PBS for 20 min at room temperature. Subsequently, cells were
permeabilized for 5 min at room temperature in 0.2% Triton X-100
in PBS, washed in PBS and subjected to labeling with rhodamine-
conjugated phalloidin for 30 min at 37‡C or stained with primary
antibodies directed against ZO-1, cadherin-5 (VE-cadherin) or L-cat-
enin (purchased from BD Transduction Laboratories). Following
washing primary antibodies were labeled by treatment for 30 min at
37‡C with the respective secondary antibodies coupled to FITC. Cells
were washed again and then mounted in mowiol with 4% n-propyl-
gallate as antifade agent. Microscopic inspection employed a DM
RXA £uorescence microscope (Leica, Wetzlar, Germany) connected
to a cooled CCD camera.
3. Results and discussion
3.1. E¡ects of Rho activation and inactivation on the
endothelial actin cytoskeleton and components of
interendothelial junction complexes
Bacterial toxins have provided a powerful means of altering
in a speci¢c manner the activity of Rho GTPases (for review
see [26,27]). The C3 exoenzyme of C. limosum has been of
particular interest since it inactivates Rho by ADP ribosyla-
tion at asparagine 41 without a¡ecting other members of the
Rho superfamily like Rac and Cdc42 [28]. Constant activation
of Rho can also a¡ect its dynamic cycling between the GTP
and GDP bound conformation and can thereby interfere with
a regulatory function of Rho. Such activation can be achieved
by E. coli cytotoxic necrotizing factor (CNF) 1 which deami-
dates glutamine 63 of Rho [23]. Thus we decided to speci¢-
cally manipulate Rho in microvascular endothelial cells by
employing the C3 protein toxin and CNF1 in order to eluci-
date the importance of Rho signaling on leukocyte^endothe-
lium interactions and leukocyte transendothelial migration.
First, we needed to establish that the bacterial toxins had
the anticipated e¡ects on the endothelial actin cytoskeleton.
Monolayers of the microvascular endothelial cell line HMEC-
1 were subjected to toxin treatment for di¡erent times and
subsequently stained with rhodamine^phalloidin to visualize
F-actin. Since the C3 exoenzyme does not penetrate the plas-
ma membrane the experiments employed a C2IN-C3 fusion
toxin in which C3 had been fused to the N-terminal part of
the C. botulinum C2I toxin thereby enabling cellular uptake
when used in conjunction with the membrane binding C2II
protein [24]. Fig. 1 (upper panels) reveals that Rho inactiva-
tion or activation in HMEC-1 by C2IN-C3 or CNF1, respec-
tively, resulted in a signi¢cant loss (C2IN-C3) or a marked
increase (CNF1) in actin stress ¢bers. The e¡ects of both
toxins were reversible and the appearance of the actin cyto-
skeleton returned to normal following removal of the toxins
and incubation of the HMEC-1 in toxin-free medium for a
period of at least 4 h (not shown).
Given these e¡ects on the actin cytoskeleton we next ana-
lyzed whether Rho inactivation or activation a¡ected the lo-
calization of proteins of endothelial junctions which are linked
directly or via adapter proteins to the actin cytoskeleton. Nei-
ther ZO-1, a component of tight junctions, nor VE-cadherin
or L-catenin, which are found in adherens junctions, are al-
tered following C2IN-C3 treatment and stress ¢ber reduction.
Rho activation by CNF1 also has no marked e¡ect on the
localization of the junctional markers although the ZO-1, VE-
cadherin and L-catenin stainings seem to be more pronounced
in the CNF1-treated cells (Fig. 1, lower panels). Thus,
although Rho family GTPases have emerged recently as reg-
ulators of cadherin-mediated cell^cell adhesion, it appears
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Fig. 1. E¡ect of Rho inactivation or activation on endothelial F-actin and components of interendothelial junctions. A: HMEC-1 monolayers
were incubated with the C2IN-C3 or CNF1 toxins, as described in Section 2. At the times indicated cells were ¢xed and processed for rhod-
amine^phalloidin staining to visualize F-actin. B: HMEC-1 were treated with the C2IN-C3 or CNF1 toxins for 3 and 16 h, respectively. Subse-
quently, cells were ¢xed and processed for indirect immuno£uorescence using antibodies against the cell^cell junction proteins ZO-1, VE-cadher-
in, and L-catenin. Scale bar represents 10 Wm.
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that in HMEC-1 Rho itself has no or only a minor e¡ect on
the appearance of interendothelial junctions. However,
although the junction components analyzed appear una¡ected
or hardly a¡ected in their localization over the entire time
course of toxin treatment we cannot exclude a more subtle
e¡ect on the dynamics of adherens junctions which is not
evident in our morphological analyses. Moreover, it remains
possible that Rac1 and Cdc42 are more important for regu-
lating endothelial adherens junctions than RhoA which is tar-
geted by the toxins in our experimental setup (for review see
[20]).
3.2. The transendothelial migration of monocytes is a¡ected by
Rho inactivation or activation
To elucidate whether endothelial Rho participates in regu-
lating endothelium^leukocyte interactions and/or the transen-
dothelial migration of leukocytes, endothelial monolayers
were pretreated with the bacterial toxins for 3 h (C2IN-C3)
or 16 h (CNF1), and then subjected to monocyte adhesion
and transmigration assays. Moreover, the barrier function of
the toxin-treated endothelial cells was characterized by mea-
suring macromolecule £ux across endothelial monolayers. Du-
ration of the toxin pretreatment and concentration of the
toxin employed were chosen to have the maximum stabilizing
or destabilizing e¡ect on the endothelial F-actin (see Fig. 1).
Moreover, we veri¢ed through wash-out experiments that the
toxin e¡ects, i.e. destabilization or stabilization of stress ¢bers,
persisted in HMEC-1 pretreated with the toxins and kept in
toxin-free medium for the duration of our adhesion (30 min)
and transendothelial migration assays (2^4 h), respectively
(not shown).
Fig. 2 summarizes the results obtained following Rho in-
activation through the C2IN-C3 fusion toxin which was in-
troduced via the C2IIa membrane binding component. In the
experiments shown toxin-treated endothelial cells are com-
pared to non-treated control cells since a series of control
experiments had established that administration of the mem-
brane binding C2IIa component alone had no signi¢cant ef-
fect on endothelial permeability, leukocyte adhesion and
transmigration (not shown). Moreover, previous experiments
had revealed that C2IN itself is enzymatically inactive and
that the individual toxin components (C2IN-C3 and C2IIa)
have no e¡ect on cell morphology [24,29]. Pretreatment of the
endothelial cells with both, the C2IN-C3 fusion toxin and the
C2IIa membrane binding component, which leads to a desta-
bilization of endothelial F-actin (see Fig. 1), induces a signi¢-
cant increase in the adhesion of monocytes (Fig. 2, 3 h col-
umn). An even greater stimulation of monocyte adhesion is
observed when the C2IN-C3 and C2IIa toxins were also
present during monocyte adhesion thereby a¡ecting both, en-
dothelial and monocytic Rho (Fig. 2, 3 h+1 h column). The
stimulatory e¡ect is less pronounced when the endothelial cells
were activated by cultivation in the presence of TNF-K for
16 h prior to the toxin treatment. Under these conditions the
TNF-K-induced increase in adhesion was approximately 110%
in the case of untreated control cells, 55% for HMEC-1 pre-
treated with the toxin for 3 h and 35% in cases where adhe-
sion was analyzed in the presence of toxin (3 h+1 h; not
shown). Taken together, this indicates that adhesion mole-
cules mediating leukocyte^endothelium interactions under
the conditions chosen, i.e. integrins on monocytes and
ICAM-1 and VCAM-1 on the endothelium [14], require
Rho activity for optimal presentation on the cell surface
and that inactivation of Rho results in a higher and possibly
aberrant surface concentration of interaction-competent adhe-
sion molecules.
A contrasting and even more signi¢cant e¡ect is observed
when the migration of monocytes through C2IN-C3-treated
HMEC-1 monolayers is analyzed (Fig. 2). While the transen-
dothelial permeability remains una¡ected, toxin treatment re-
sults in a reduction of the rate of transmigration as compared
to that through control monolayers. The e¡ect is observed for
both, unstimulated and TNF-K-stimulated HMEC-1 although
the reduction is somewhat less pronounced in the latter case.
Fig. 2. Inactivation of endothelial Rho by C2IN-C3 a¡ects mono-
cyte^endothelium adhesion and monocyte transendothelial migra-
tion. HMEC-1 were pretreated with the C2IN-C3 toxin for 3 h and
then subjected to permeability, monocyte adhesion and transmigra-
tion assays in either toxin-free medium (3 h columns) or in the pres-
ence of toxin (3 h+30 min, 3 h+1 h and 3 h+2 h columns, respec-
tively). The latter experimental conditions were chosen to inactivate
Rho proteins in both, endothelial cells and monocytes. In each as-
say results obtained for the toxin-treated cells were compared to
those of control cells kept for the same time in toxin-free medium.
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This could suggest that the TNF-K-induced expression of en-
dothelial adhesion molecules, which is required for e⁄cient
transmigration, could bypass to some extent a need for Rho
signaling. The inhibitory e¡ect of the Clostridium toxin on
transendothelial migration is even more pronounced when
the toxin is also present during the actual course of the trans-
migration assay thereby also a¡ecting Rho in the migrating
monocytes. Since Rho signaling is known to be required for
cell migration (for review see [2^4]) the strong inhibition seen
in these experiments is expected and thus serves as a positive
control for the validity of our assay.
In contrast to C3-mediated Rho inactivation, activation of
endothelial Rho by CNF1 treatment has no e¡ect on mono-
cyte adhesion. The transmigration of monocytes through
CNF1-treated endothelial monolayers, however, is slightly re-
duced as compared to non-treated controls and this reduction
is observed for both non-stimulated and TNF-K-stimulated
endothelial cells (Fig. 3). Moreover, CNF1 treatment results
in a decreased transendothelial permeability of macromol-
ecules (Fig. 3) and an increased transendothelial resistance
(not shown). Thus in line with the somewhat stronger concen-
tration of endothelial junction proteins in CNF1-treated en-
dothelial monolayers (see above) the toxin-mediated activa-
tion of Rho appears to trigger a stronger interendothelial
adhesion with a resultant reduction in transendothelial perme-
ability and cell migration.
At present, it is not known whether in our cell system Rho
acts directly on components of interendothelial junctions
thereby a¡ecting the tightness of cell^cell contacts or whether
it acts through regulation of the actin cytoskeleton dynamics
and/or the actin cytoskeleton/junction interface. Proteins in-
teracting with and regulating Rho have been described in ep-
ithelial cell^cell junctions, e.g. p120/catenin which inactivates
the intrinsic guanine nucleotide exchange activity of RhoA
thereby causing inactivation (for review see [20]), but it is
not known whether such interactions are of functional rele-
vance for the Rho-dependent regulation of endothelial barrier
functions. Subtle or perhaps even more pronounced di¡eren-
ces between the cell^cell contacts of di¡erent types of cells can
probably be expected and can explain the di¡ering e¡ects of
C3-mediated Rho inactivation on the recruitment of cadherin
to intercellular junctions. While injection of C3 into keratino-
cytes inhibits the accumulation of cadherin at cell^cell adhe-
sion sites induced in the presence of calcium [30], introduction
of the toxin into endothelial monolayers does not a¡ect the
junctional localization of VE-cadherin or the endothelial bar-
rier formation (see Figs. 1 and 2). Future experiments have to
reveal whether such di¡erences are due to a speci¢c junction
arrangement in microvascular endothelial cells and/or re£ect
an altered Rho requirement in developing as compared to
established cell^cell contacts.
3.3. Conclusions
Bacterial toxins were employed to alter Rho activity in
monolayers of microvascular endothelial cells. While Rho ac-
tivation results in an increased endothelial barrier formation,
Rho inactivation has no e¡ect on the transendothelial perme-
ability or the localization of proteins found in tight and ad-
herens junctions. However, interfering with Rho dynamics by
permanently activating or inactivating the GTPase reduces the
rate of migration of blood monocytes through the toxin-
treated endothelial monolayers. Since actin cytoskeleton dy-
namics in the endothelium are thought to be required for
e⁄cient leukocyte transmigration, the experiments point to-
wards an important role of endothelial Rho in regulating
these dynamics. Thus, not only the Rho GTPase-regulated
cytoskeleton of migrating leukocytes but also that of the en-
dothelial layer of the microvasculature appears to play an
active role in supporting leukocyte extravasation.
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